Study summary
Weekly semaglutide cut heavy drinking days more than therapy alone
41.1percentage-point drop in heavy drinking days, vs 26.4 with placebo
What was tested
Weekly semaglutide 2.4 mg or placebo for 26 weeks, both with cognitive behavioural therapy, in treatment-seeking adults with moderate to severe alcohol use disorder and obesity.
What they found
- Heavy drinking days fell 41.1 percentage points with semaglutide vs 26.4 with placebo.
- Side effects were mostly mild, temporary stomach upset.
What it means
The strongest evidence yet that GLP-1 drugs reduce drinking; larger trials are under way.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.